Seneca Partners
VC Fund
Birmingham, United States
Seneca Partners is a middle market focused investment banking and private investing firm. Their transaction and investing experience includes most industry sectors, however has strong experience in manufacturing, healthcare and business services.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Seneca Partners invests in
Stages Seneca Partners invests in
Countries Seneca Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $847k–$1.7M
- Series A
- $2.5M–$5.4M
- Venture - Series Unknown
- $1.1M–$8.1M
Investment Focus
Industry
- Health Care 4 (24%)
- Biotechnology 4 (24%)
- Medical 2 (12%)
- Dental 1 (6%)
- Farming 1 (6%)
Stage
- Venture - Series Unknown 5 (29%)
- Seed 2 (12%)
- Series A 2 (12%)
- Series E 1 (6%)
- Private Equity 1 (6%)
Country
- United Kingdom 9 (53%)
- United States 3 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tony Zambelli
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including mild to moderate obstructive sleep apnea (OSA). Vivos believes that its Vivos System technology represents the first clinically effective non-surgical,non-invasive, non-pharmaceutical and cost-effective alternative for people with mild-to-moderate OSA. Combining technologies and protocols that can alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.Vivos Therapeutics was established on January 1, 2013 by Dave Singh and R. Kirk Huntsman in Littleton, Colorado. | $2.3M / Post-IPO Equity / Apr 07, 2026 | ||
| Circadence Corporation is a market leader in next-generation cybersecurity readiness. Powered by a culture of innovation and the demands of an evolving cyber landscape, Circadence offers cyber range solutions and cybersecurity learning platforms, running on Microsoft Azure, that leverage custom content to address critical security challenges forenterprise, government, and academic institutions. Circadence's solutions deliver persistent, immersive and true-to-life experiences that match and adapt to contemporary threat environments. Circadence is also a Microsoft Gold Partner. | $16.4M / Private Equity / Mar 04, 2026 | ||
| Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including mild to moderate obstructive sleep apnea (OSA). Vivos believes that its Vivos System technology represents the first clinically effective non-surgical,non-invasive, non-pharmaceutical and cost-effective alternative for people with mild-to-moderate OSA. Combining technologies and protocols that can alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.Vivos Therapeutics was established on January 1, 2013 by Dave Singh and R. Kirk Huntsman in Littleton, Colorado. | $7.5M / Post-IPO Equity / Jun 12, 2024 | ||
| ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs. | $3.2M / Venture - Series Unknown / Nov 15, 2018 | ||
| SuperCarers Founded by Adam and Daniel Pike, they match families with vetted, reliable & compassionate carers. | $5.4M / Series A / Mar 26, 2018 | ||
| BondMason was formed in 2014 to enable investors to achieve returns from the UK property market. We provide insights, analysis, and access to investment opportunities relating to UK residential property. | $2.6M / Venture - Series Unknown / Mar 13, 2018 | ||
| ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs. | $8.1M / Venture - Series Unknown / Sep 25, 2017 | ||
| The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing needfor new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance. | $2M / Venture - Series Unknown / Sep 19, 2017 | ||
| Vapour Cloud is a West Yorkshire cloud technology provider to SME resellers. Vapour provides SME resellers with the point of access to highly competent independent, private network infrastructure, a choice of leading network providers, and a scalable platform for growth, backed by comprehensive training and fully managed installation and support. | $1.3M / Venture - Series Unknown / Jun 20, 2017 | ||
| Vapour Cloud is a West Yorkshire cloud technology provider to SME resellers. Vapour provides SME resellers with the point of access to highly competent independent, private network infrastructure, a choice of leading network providers, and a scalable platform for growth, backed by comprehensive training and fully managed installation and support. | $1.1M / Venture - Series Unknown / Jun 01, 2016 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Seneca Partners invest in?
Seneca Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Seed stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Seneca Partners's check size?
Seneca Partners typically joins rounds of $847k–$1.7M at Seed, $2.5M–$5.4M at Series A and $1.1M–$8.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Seneca Partners participates in.
How do I contact Seneca Partners?
Public channels for Seneca Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Seneca Partners?
The team at Seneca Partners includes Tony Zambelli (Co-Founder and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
